PsyAccess
Spravato®Registry-verifiedDesignated-centers model

Zentrum für Angst und Depression Zürich (ZADZ)

Zürich, Switzerland

Treatment & access

  • Treatments offeredesketamine (Spravato)
  • Access routepublic_reimbursed
  • Price informationReimbursed by mandatory health insurance (OKP/AOS) per SL Limitatio
  • ReimbursementBAG Spezialitätenliste Limitatio: cantonal psychiatric care mandate required; list valid 2025-10-01 to 2028-09-30 How reimbursement works in Europe →
  • Phone+41 44 386 66 00
  • Websitehttps://zadz.ch/

About this provider

The Zentrum für Angst- und Depressionsbehandlung Zürich (ZADZ), located at Riesbachstrasse 61 in Zurich's Seefeld district, is a psychiatric-psychotherapeutic outpatient clinic specialising in anxiety and depression treatment for patients of all ages. A team of around 40, including specialists in psychiatry and psychotherapy and psychological psychotherapists, provides assessment and integrative treatment, complemented by certified respiratory and physiotherapists, career coaching, social work, nutritional counselling and psychiatric nursing. ZADZ is part of the Clienia Group and participates in clinical research, primarily with the Psychiatric University Hospital Zurich.

Services & programs

  • Outpatient psychiatric and psychotherapeutic treatment of anxiety disorders and depression
  • Psychiatric assessment and integrative treatment planning
  • Psychological psychotherapy
  • Complementary therapies (respiratory therapy, physiotherapy, nutritional counselling)
  • Career coaching, social work and psychiatric nursing
  • Participation in clinical research projects with the Psychiatric University Hospital Zurich

Common questions

How do I become a patient at ZADZ?

ZADZ is an outpatient clinic reachable on 044 386 66 00 or info@zadz.ch. For Spravato treatment under Swiss basic insurance, a psychiatrist must confirm the Limitatio criteria and obtain the insurer's cost approval (Kostengutsprache) before the first dose.

What does Swiss reimbursement of Spravato require?

Adults 18-74 whose current episode has not responded to at least two antidepressants plus one augmentation attempt, CGI-S severity of 5 or more, insurer pre-approval before the first administration, and a maximum reimbursed duration of 10 months.

Looking at alternatives? One of the BAG-designated Spravato centers; see the country guide and the limited-medical-use PAT program.

Verification

This record was taken directly from an official registry or program list and is re-checked on a rolling cadence.

Spotted an error? See our methodology for how records are checked and how to report a correction.